1. Catalog
  2. GREPNSMG2521 - CME/CMLE - NSCLC Biomarker Testing ...
GREPNSMG2521 - CME/CMLE - NSCLC Biomarker Testing Learning Collaborative Meeting 2
Course Description

NSCLC Biomarker Testing Learning Collaborative Meeting 2 

As advances in targeted treatments for NSCLC continue to emerge, keeping up with this rapidly evolving landscape has posed challenges for the pathology team, necessitating education on advances and key considerations in emerging NSCLC biomarkers and treatments, testing considerations, and clinical practice guidelines. To equip members of the pathology team, ASCP is hosting a learning collaborative where pathologists and laboratory professionals will discuss ways to improve biomarker testing processes in patients with NSCLC.  

Activity Agenda 

  • Introductions 

  • Program overview 

  • Reviewing clinical practice guideline recommendations 

  • Recent updates and advances in biomarker testing 

  • Discussing local application, practical challenges, and opportunities for improvement 

 
Target Audience 
This activity has been designed to meet the educational needs of pathologists and laboratory professionals  


Faculty/Authors
Joseph Kim, MD, MPH, MBA
President, Q Synthesis LLC
Langhorne, PA 

Physician's Competency: Patient Care, Medical Knowledge 

CME/CMLE Credit: 1.0
Estimated Completion Time: 1 hour
Format: Online educational activity

Credit Designation Statement

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. 

The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.  

ASCP designates this activity for a maximum of 1.0 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.  

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. 

Method of Participation
To complete the activity and receive credit, the participant must have attended the Learning Collaborative meeting. CME/CMLE certificates will be provided online 

Commercial Support 
This activity was funded by an independent educational grant from AstraZeneca and Daiichi Sankyo Inc..   


Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Complete the Demographic Survey.
  3. Submit the course Evaluation.
  4. Enter the maximum number of credits offered and click Claim CMLE to register credit.


Faculty Disclosures 

Technical Considerations 

Release Dates: 4/28/2025        
Review Date:
Expiration Date: 12/15/2025   

Course Objectives

Upon completion of this activity, you will be able to:

  • Discuss the latest research in new and emerging biomarkers for NSCLC   

  • Prepare for potential changes to biomarker testing workflows as new therapies for patients with advanced NSCLC emerge  

  • Outline the role of different HER2 testing methods in NSCLC to identify overexpression, amplification, and mutations 

  • Apply current practice guidelines for biomarker testing in patients with NSCLC 

  • Optimize NSCLC specimen protocols to ensure sufficient sample sizes for biomarker testing 

  • Take a more active role in their institutions to drive appropriate and equitable biomarker testing for patients with NSCLC 

 


  

 
Summary
Availability:
On-Demand
Credit Offered:
1 CME/CMLE Credit
Powered By